Respiratory Phase 3 Readout Calendar
Industry-sponsored respiratory trials with primary completion in the next 12 months or last 12 months.
Data last updated November 12, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularRespiratoryRare DiseaseInfectious DiseaseMusculoskeletalDermatologyOphthalmology
15
Next 6 months
26
Next 12 months
21
Results posted
146
Phase 3 Respiratory
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 respiratory trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What respiratory trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 respiratory trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which respiratory trials have already read out?
The "recently read out" section shows Phase 3 respiratory trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Respiratory slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Respiratory landscape →
Recently read out & awaiting topline — Respiratory
· 8Phase 3 respiratory trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Placebo | Chronic Obstructive Pulmonary Disease (COPD) | Completed | Q1 2026 2026-03-06 | Completed · awaiting
Updated 8mo ago
| NCT06040086 |
| AstraZeneca | Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). | Chronic Obstructive Pulmonary Disease (COPD) | Completed | Q1 2026 2026-02-26 | Completed · awaiting
Updated 8mo ago
| NCT05742802 |
| United Therapeutics | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Asset: Placebo | Idiopathic Pulmonary Fibrosis +1 | Completed | Q1 2026 2026-02-02 | Completed · awaiting
Updated 7mo ago
| NCT04708782 |
| Vertex Pharmaceuticals Incorporated | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older Asset: ELX/TEZ/IVA | Cystic Fibrosis | Completed | Q1 2026 2026-01-29 | Completed · awaiting
Updated 8mo ago
| NCT05153317 |
| AstraZeneca | A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). Asset: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate | Chronic Obstructive Pulmonary Disease | Completed | Q1 2026 2026-01-22 | Completed · awaiting
Updated 8mo ago
| NCT06067828 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | Completed | Q1 2026 2026-01-19 | Completed · awaiting
Updated 7mo ago
| NCT05166889 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. Asset: Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | Completed | Q1 2026 2026-01-19 | Completed · awaiting
Updated 7mo ago
| NCT05158387 |
| Chiesi Farmaceutici S.p.A. | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD Asset: Beclomethasone Dipropionate | COPD +1 | Completed | Q1 2026 2026-01-12 | Completed · awaiting
Updated 9mo ago
| NCT04320342 |
Upcoming respiratory readouts — next 12 months
· 26Industry Phase 3 respiratory trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Sanofi | A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD Asset: Itepekimab (SAR440340) | Chronic Obstructive Pulmonary Disease | Completed | Q4 2026 2026-12-01 (est.) | Estimated · stale
Updated 17mo ago
| NCT06208306 |
| Beijing Continent Pharmaceutical C… | Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | Radiation-induced Lung Injury +1 | Recruiting | Q4 2026 2026-12-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT07388680 |
| Qilu Pharmaceutical Co., Ltd. | Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections Asset: Meropenem and Pralurbactam | Hospital-acquired Bacterial Pneumonia (HABP) +4 | Recruiting | Q4 2026 2026-12 (est.) | Estimated · stale
Updated 15mo ago
| NCT07089186 |
| Inmunotek S.L. | Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Asset: 10,000 MM09 | Rhinitis, Allergic +2 | Recruiting | Q4 2026 2026-12 (est.) | Estimated · stale
Updated 18mo ago
| NCT04435990 |
| Guangzhou JOYO Pharma Co., Ltd | SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) Asset: SC1011 | Idiopathic Pulmonary Fibrosis | Recruiting | Q4 2026 2026-12-31 (est.) | Estimated · stale
Updated 24mo ago
| NCT06125327 |
Unlock 21 more respiratory readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.